Table 1.
Characteristics of study participants at baseline by randomised treatment
| Placebo | 0.45 g/day | 0.9 g/day | 1.8 g/day | P* | |
|---|---|---|---|---|---|
| n = 70 | n = 80 | n = 80 | n = 80 | ||
| Gender | |||||
| Male (%) n | 31, 44 | 30, 38 | 30, 38 | 29, 36 | |
| Female (%) n | 39, 56 | 50, 62 | 50, 62 | 51, 64 | |
| Age, years | 55.37 ± 6.85 | 55.13 ± 6.84 | 55.15 ± 6.60 | 55.02 ± 6.71 | 0.995 |
| BMI, kg/m2 | 26.13 ± 3.72 | 25.14 ± 3.88 | 26.16 ± 4.01 | 25.15 ± 3.50 | 0.172 |
| Waist circumference, cm | 89.50 ± 11.74 | 87.33 ± 11.80 | 89.42 ± 11.87 | 88.03 ± 11.00 | 0.602 |
| Plasma fatty acid, % total | |||||
| EPA | 1.17 ± 0.59 | 1.10 ± 0.61 | 1.11 ± 0.56 | 1.10 ± 0.57 | 0.901 |
| DPA | 0.65 ± 0.10 | 0.64 ± 0.12 | 0.64 ± 0.13 | 0.65 ± 0.13 | 0.897 |
| DHA | 2.37 ± 0.68 | 2.44 ± 0.77 | 2.36 ± 0.67 | 2.47 ± 0.68 | 0.961 |
Data are presented for subjects who completed the study and for whom DNA was available (n = 310). Measurements taken at baseline after 4-week run-in on normal diet with olive oil placebo supplement are shown for each randomised treatment group: placebo and EPA and DHA (1.51:1) at the daily doses shown. Values are n (%) for male/female or mean ± SD for all other variables
BMI body mass index; EPA eicosapentaenoic acid; DPA docosapentaenoic acid; DHA docosahexaenoic acid
* Significance of differences between treatment groups assessed by one-way ANOVA. P-value for difference in age, adjusted for BMI, gender and ethnicity; for differences in BMI and waist circumference, adjusted for age, gender and ethnicity; for differences in plasma fatty acid proportions, adjusted for BMI, age, gender and ethnicity